Healthcare Industry News: Allergan
News Release - December 14, 2006
CyDex Announces Captisol Technology Used in Recently Launched Injection Formulation of Antipsychotic Medication ABILIFY(R) (aripiprazole)LENEXA, Kan., Dec. 14 (HSMN NewsFeed) -- CyDex, Inc., a specialty pharmaceutical company developing improved products through innovative drug delivery, today announced ABILIFY® Injection, a new intramuscular form of the antipsychotic medication ABILIFY® (aripiprazole) from Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd., contains CyDex's Captisol Technology. ABILIFY Injection is the third drug formulation commercially available in the United States utilizing CyDex's Captisol® enabling technology. The U.S. Food and Drug Administration (FDA) approved ABILIFY Injection on September 20, 2006.
CyDex's patented Captisol technology improves water solubility, bioavailability and complexation characteristics of insoluble and/or unstable drugs. In addition to injectable products, the CyDex pipeline of licensed and proprietary Captisol-enabled formulations targets a range of market segments including oral solutions and capsules, ophthalmic solutions, oral solids and inhalation.
"Bristol-Myers Squibb's and Otsuka's launch of ABILIFY Injection further demonstrates the value of Captisol in supporting line extension strategies for successful pharmaceuticals," said CyDex Chief Executive Officer John M. Seibert. "An expanding roster of CyDex pharmaceutical industry partners recognize that Captisol offers tremendous solubility advantages, and we look forward to future product launches by these partners in the years ahead."
About CyDex, Inc.
CyDex is a specialty pharmaceutical company developing proprietary products and licensing its Captisol® enabling technology. CyDex is bringing important new medications to patients by developing its own pipeline of proprietary products with advanced drug delivery solutions, and by partnering with the world's leading pharmaceutical and biotechnology companies. In addition to Geodon for Injection and Vfend IV, marketed globally by Pfizer Inc., and ABILIFY Injection marketed in the United States by Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd., CyDex has development agreements with Allergan, Inc.; Bristol-Myers Squibb; Daiichi-Asubio Pharma Co., Ltd., of Japan; Merck & Co., Inc.; Mitsubishi Corporation, of Japan; OSI Pharmaceuticals, Inc.; PTC Pharma AG, of Switzerland; TargeGen, Inc.; Taisho Pharmaceuticals of Japan and Teva Pharmaceutical Industries Ltd., of Israel. CyDex also has clinical use agreements with major pharma and biotech companies. CyDex is a privately held company located in suburban Kansas City. To learn more about the company, please visit http://www.cydexinc.com .
Captisol and Captisol-enabled are registered trademarks of CyDex, Inc. ABILIFY is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Geodon IM and Vfend IV are registered trademarks of Pfizer Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.